Terms: = Thyroid cancer AND CALR, ENSG00000179218, 811, P27797, SSA, RO, FLJ26680, cC1qR AND Treatment
41 results:
1. A phase 2 study of MK-2206 in patients with incurable adenoid cystic carcinoma (Alliance A091104).
Ho AL; Foster NR; Deraje Vasudeva S; Katabi N; Antonescu CR; Frenette GP; Pfister DG; Erlichman C; Schwartz GK
Cancer; 2024 Mar; 130(5):702-712. PubMed ID: 37947157
[TBL] [Abstract] [Full Text] [Related]
2. A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced or metastatic solid tumors.
Huang Z; Xu Y; Hong W; Gong L; Chen K; Qin J; Xie F; Wang F; Tian X; Meng X; Feng W; Li L; Zhang B; Kang X; Fan Y
Front Immunol; 2023; 14():1258573. PubMed ID: 37936687
[TBL] [Abstract] [Full Text] [Related]
3. Evaluation of progression-free survival as a surrogate endpoint for overall survival in locally advanced or metastatic differentiated thyroid cancer: a systematic review.
Yang S; Zhan J; Xu X
Endocrine; 2023 Dec; 82(3):491-497. PubMed ID: 37702900
[TBL] [Abstract] [Full Text] [Related]
4. Characteristics and response cutoff of octreotide suppression test in thyrotrophin (TSH)-secreting pituitary adenomas.
Liu J; Yang Y; Duan L; Chai X; Zhu H; Deng K; Lian X; Yao Y
Clin Endocrinol (Oxf); 2023 Sep; 99(3):306-314. PubMed ID: 37144621
[TBL] [Abstract] [Full Text] [Related]
5. An Analysis of Environment-, Individual-, and Tumor-Related Factors Impacting Hypovitaminosis D in Patients with Malignant Tumors.
Bai Y; Wen YQ; Jiao Y; Zhang YH; Ma X
Nutr Cancer; 2023; 75(5):1340-1348. PubMed ID: 36988095
[TBL] [Abstract] [Full Text] [Related]
6. Combination of transsphenoidal endoscopic surgery and presurgical somatostatin analogs in thyrotropin (TSH)-secreting pituitary adenomas: treatment outcome and long-term remission at a single pituitary center.
Liu J; Yang Y; Duan L; Chai X; Zhu H; Deng K; Lian X; Yao Y
Front Endocrinol (Lausanne); 2022; 13():1061029. PubMed ID: 36518240
[TBL] [Abstract] [Full Text] [Related]
7. Development and validation of nomograms for predicting overall survival and cancer specific survival in locally advanced breast cancer patients: A SEER population-based study.
Yin F; Wang S; Hou C; Zhang Y; Yang Z; Wang X
Front Public Health; 2022; 10():969030. PubMed ID: 36203704
[TBL] [Abstract] [Full Text] [Related]
8. Development and validation of a nomogram model for cancer-specific survival of patients with poorly differentiated thyroid carcinoma: A SEER database analysis.
Jin S; Liu H; Yang J; Zhou J; Peng D; Liu X; Zhang H; Zeng Z; Ye YN
Front Endocrinol (Lausanne); 2022; 13():882279. PubMed ID: 36176465
[TBL] [Abstract] [Full Text] [Related]
9. Profile of Levothyroxine Replacement Therapy in Graves' Disease Patients with Hypothyroidism Post-Radioactive Iodine Ablation: Focus on Different Weight-Based Regimens.
Mathiphanit S; Yenseung N; Chatchomchuan W; Butadej S; Nakasatien S; Wanothayaroj E; Rajatanavin R; Himathongkam T; Thewjitcharoen Y
J ASEAN Fed Endocr Soc; 2022; 37(1):62-68. PubMed ID: 35800593
[TBL] [Abstract] [Full Text] [Related]
10. Pregnancy Outcomes in thyroid cancer Survivors: A Propensity Score-Matched Cohort Study.
Cao Q; Zhu H; Zhang J; Li Y; Huang W
Front Endocrinol (Lausanne); 2022; 13():816132. PubMed ID: 35250872
[TBL] [Abstract] [Full Text] [Related]
11. Construction of a Diagnostic Model for Lymph Node Metastasis of the Papillary thyroid Carcinoma Using Preoperative Ultrasound Features and Imaging Omics.
Zhang C; Cheng L; Zhu W; Zhuang J; Zhao T; Li X; Wang W
J Healthc Eng; 2022; 2022():1872412. PubMed ID: 35178222
[TBL] [Abstract] [Full Text] [Related]
12. Clinical features, treatments, and outcomes of patients with anti-
Xu Q; Zhu Y; Wang Q; Han J; Mao F; Zeng S; Chen S; Zhao C; Gu M; Li Z; Luo X; Fu X; Huang Y
Front Biosci (Landmark Ed); 2021 Sep; 26(9):496-503. PubMed ID: 34590462
[No Abstract] [Full Text] [Related]
13. Systematic review of health-related quality of life following thyroid cancer.
Walshaw EG; Smith M; Kim D; Wadsley J; Kanatas A; Rogers SN
Tumori; 2022 Aug; 108(4):291-314. PubMed ID: 34387109
[TBL] [Abstract] [Full Text] [Related]
14. Metastatic Medullary thyroid cancer: The Role of 68Gallium-DOTA-Somatostatin Analogue PET/CT and Peptide Receptor Radionuclide Therapy.
Hayes AR; Crawford A; Al Riyami K; Tang C; Bomanji J; Baldeweg SE; Wild D; Morganstein D; Harry A; Grozinsky-Glasberg S; Oleinikov K; Khoo B; Caplin ME; Nicolas GP; Grossman AB
J Clin Endocrinol Metab; 2021 Nov; 106(12):e4903-e4916. PubMed ID: 34379772
[TBL] [Abstract] [Full Text] [Related]
15. Favorable outcomes of papillary thyroid microcarcinoma concurrent with Graves' disease after radioactive iodine therapy.
Nishihara E; Ito Y; Kudo T; Ito M; Fukata S; Nishikawa M; Akamizu T; Miyauchi A
Endocr J; 2021 Jun; 68(6):649-654. PubMed ID: 33551434
[TBL] [Abstract] [Full Text] [Related]
16. Image-Guided Thermal Ablation as an Alternative to Surgery for Papillary thyroid Microcarcinoma: Preliminary Results of an Italian Experience.
Mauri G; Orsi F; Carriero S; Della Vigna P; De Fiori E; Monzani D; Pravettoni G; Grosso E; Manzoni MF; Ansarin M; Giugliano G
Front Endocrinol (Lausanne); 2020; 11():575152. PubMed ID: 33488514
[TBL] [Abstract] [Full Text] [Related]
17. An Analysis of 1-Year Charges for Head and Neck cancer: Targets for Value-Based Interventions.
Pang J; Crawford K; Faraji F; Ramsey C; Kemp A; Califano JA
Otolaryngol Head Neck Surg; 2020 Sep; 163(3):546-553. PubMed ID: 32450778
[TBL] [Abstract] [Full Text] [Related]
18. The effect of disease activity on thyroid nodules in patients with acromegaly.
Kan S; Kizilgul M; Celik B; Beysel S; Caliskan M; Apaydin M; Ucan B; Cakal E
Endocr J; 2019 Apr; 66(4):301-307. PubMed ID: 30745501
[TBL] [Abstract] [Full Text] [Related]
19. Comparison of Mean Platelet Volume, Platelet Count, Neutrophil/ Lymphocyte Ratio and Platelet/Lymphocyte Ratio in the Euthyroid, Overt Hypothyroid and Subclinical Hyperthyroid Phases of Papillary thyroid Carcinoma.
Kutluturk F; Gul SS; Sahin S; Tasliyurt T
Endocr Metab Immune Disord Drug Targets; 2019; 19(6):859-865. PubMed ID: 30727930
[TBL] [Abstract] [Full Text] [Related]
20.
Jia D; Augert A; Kim DW; Eastwood E; Wu N; Ibrahim AH; Kim KB; Dunn CT; Pillai SPS; Gazdar AF; Bolouri H; Park KS; MacPherson D
Cancer Discov; 2018 Nov; 8(11):1422-1437. PubMed ID: 30181244
[No Abstract] [Full Text] [Related]
[Next]
